Inspire Investing LLC Invests $405,000 in Codexis, Inc. (NASDAQ:CDXS)

Inspire Investing LLC acquired a new stake in Codexis, Inc. (NASDAQ:CDXS) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 84,988 shares of the biotechnology company’s stock, valued at approximately $405,000. Inspire Investing LLC owned 0.10% of Codexis as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. Intech Investment Management LLC purchased a new position in shares of Codexis in the 3rd quarter valued at about $66,000. Marshall Wace LLP purchased a new position in Codexis in the second quarter valued at about $89,000. Algert Global LLC lifted its position in shares of Codexis by 17.1% during the 2nd quarter. Algert Global LLC now owns 41,556 shares of the biotechnology company’s stock valued at $129,000 after acquiring an additional 6,069 shares during the period. Jackson Square Capital LLC purchased a new stake in shares of Codexis during the 4th quarter worth approximately $210,000. Finally, Squarepoint Ops LLC grew its holdings in shares of Codexis by 113.8% in the 2nd quarter. Squarepoint Ops LLC now owns 74,531 shares of the biotechnology company’s stock worth $231,000 after acquiring an additional 39,664 shares during the period. Hedge funds and other institutional investors own 78.54% of the company’s stock.

Codexis Price Performance

CDXS stock opened at $4.91 on Friday. The stock’s 50 day moving average price is $4.90 and its 200 day moving average price is $3.80. The firm has a market cap of $399.58 million, a P/E ratio of -5.64 and a beta of 2.13. The company has a debt-to-equity ratio of 0.39, a quick ratio of 3.15 and a current ratio of 3.21. Codexis, Inc. has a 1 year low of $2.53 and a 1 year high of $6.08.

Codexis (NASDAQ:CDXS) last issued its quarterly earnings data on Thursday, October 31st. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.04). Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. The company had revenue of $12.83 million during the quarter, compared to analysts’ expectations of $11.64 million. During the same quarter in the prior year, the company earned ($0.26) earnings per share. On average, sell-side analysts expect that Codexis, Inc. will post -0.77 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CDXS has been the subject of several research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $11.00 price objective on shares of Codexis in a report on Friday, November 22nd. Benchmark reiterated a “hold” rating on shares of Codexis in a research report on Monday, November 4th.

Codexis Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.